Cardiac hypertrophy is inhibited by a local pool of cAMP regulated by phosphodiesterase 2

Circulation Research

Volumn 117, Issue 8, 2015, Pages 707-719

  Zoccarato, Anna ^a   Surdo, Nicoletta C ^c   Aronsen, Jan M ^d,g   Fields, Laura A ^a   Mancuso, Luisa ^e   Dodoni, Giuliano ^e   Stangherlin, Alessandra ^a   Livie, Craig ^a   Jiang, He ^a   Sin, Yuan Yan ^b   Gesellchen, Frank ^a   Terrin, Anna ^a,e   Baillie, George S ^b   Nicklin, Stuart A ^b   Graham, Delyth ^b   Szabo Fresnais, Nicolas ^f   Krall, Judith ^f   Vandeput, Fabrice ^f   Movsesian, Matthew ^f   Furlan, Leonardo ^e   Corsetti, Veronica ^e   Hamilton, Graham ^a   Lefkimmiatis, Konstantinos ^c   Sjaastad, Ivar ^d   Zaccolo, Manuela ^a,c   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g BJØRKNES UNIVERSITY COLLEGE   (Norway)

Author keywords

cAMP; Cyclic nucleotide; Hypertrophy; Phosphodiesterases 2; Protein kinase A; Signal transduction

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE 2; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; SPLEEN EXONUCLEASE; TRANSCRIPTION FACTOR NFAT; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 2; PDE2A PROTEIN, MOUSE; PDE2A PROTEIN, RAT; PHOSPHODIESTERASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SIZE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC MANIPULATION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; ADENOVIRIDAE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARDIAC MUSCLE CELL; CARDIOMEGALY; CELL CULTURE; CELL MEMBRANE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENE VECTOR; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SECOND MESSENGER; SPRAGUE DAWLEY RAT; TIME; TIME FACTOR; WISTAR RAT;

ADENOVIRIDAE; ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; DISEASE MODELS, ANIMAL; GENETIC VECTORS; MALE; MEMBRANE MICRODOMAINS; MICE, INBRED C57BL; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RNA INTERFERENCE; SECOND MESSENGER SYSTEMS; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 84942474192     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.305892     Document Type: Article

References (57)

1. El-Armouche A, Eschenhagen T. Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev. 2009;14:225-241. doi: 10.1007/s10741-008-9132-8.
2. Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science. 2002;295:1711-1715. doi: 10.1126/science.1069982.
3. Nikolaev VO, Moshkov A, Lyon AR, Miragoli M, Novak P, Paur H, Lohse MJ, Korchev YE, Harding SE, Gorelik J. Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science. 2010;327:1653-1657. doi: 10.1126/science.1185988.
4. Hayes JS, Brunton LL, Brown JH, Reese JB, Mayer SE. Hormonally specific expression of cardiac protein kinase activity. Proc Natl Acad Sci U S A. 1979;76:1570-1574.
5. Hayes JS, Brunton LL. Functional compartments in cyclic nucleotide action. J Cyclic Nucleotide Res. 1982;8:1-16.
6. Di Benedetto G, Zoccarato A, Lissandron V, Terrin A, Li X, Houslay MD, Baillie GS, Zaccolo M. Protein kinase A type I and type II define distinct intracellular signaling compartments. Circ Res. 2008;103:836-844. doi: 10.1161/CIRCRESAHA.108.174813.
7. Scott JD, Santana LF. A-kinase anchoring proteins: getting to the heart of the matter. Circulation. 2010;121:1264-1271. doi: 10.1161/CIRCULATIONAHA.109.896357.
8. Carr DW, Stofko-Hahn RE, Fraser ID, Bishop SM, Acott TS, Brennan RG, Scott JD. Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. J Biol Chem. 1991;266:14188-14192.
9. Hulme JT, Westenbroek RE, Scheuer T, Catterall WA. Phosphorylation of serine 1928 in the distal C-terminal domain of cardiac CaV1.2 channels during beta1-adrenergic regulation. Proc Natl Acad Sci U S A. 2006;103:16574-16579. doi: 10.1073/pnas.0607294103.
10. Lygren B, Carlson CR, Santamaria K, Lissandron V, McSorley T, Litzenberg J, Lorenz D, Wiesner B, Rosenthal W, Zaccolo M, Taskén K, Klussmann E. AKAP complex regulates Ca2+ re-uptake into heart sarcoplasmic reticulum. EMBO Rep. 2007;8:1061-1067. doi: 10.1038/sj.embor.7401081.
11. Marx SO, Kurokawa J, Reiken S, Motoike H, D'Armiento J, Marks AR, Kass RS. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science. 2002;295:496-499. doi: 10.1126/science.1066843.
12. Gold MG, Lygren B, Dokurno P, Hoshi N, McConnachie G, Taskén K, Carlson CR, Scott JD, Barford D. Molecular basis of AKAP specificity for PKA regulatory subunits. Mol Cell. 2006;24:383-395. doi: 10.1016/j. molcel.2006.09.006.
13. Banky P, Newlon MG, Roy M, Garrod S, Taylor SS, Jennings PA. Isoformspecific differences between the type Ialpha and IIalpha cyclic AMPdependent protein kinase anchoring domains revealed by solution NMR. J Biol Chem. 2000;275:35146-35152. doi: 10.1074/jbc.M003961200.
14. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014;13:290-314. doi: 10.1038/nrd4228.
15. Leroy J, Abi-Gerges A, Nikolaev VO, Richter W, Lechêne P, Mazet JL, Conti M, Fischmeister R, Vandecasteele G. Spatiotemporal dynamics of beta-adrenergic cAMP signals and L-type Ca2+ channel regulation in adult rat ventricular myocytes: role of phosphodiesterases. Circ Res. 2008;102:1091-1100. doi: 10.1161/CIRCRESAHA.107.167817.
16. Stangherlin A, Gesellchen F, Zoccarato A, Terrin A, Fields LA, Berrera M, Surdo NC, Craig MA, Smith G, Hamilton G, Zaccolo M. cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes. Circ Res. 2011;108:929-939. doi: 10.1161/CIRCRESAHA.110.230698.
17. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse MJ, Pozzan T, Houslay MD, Zaccolo M. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res. 2004;95:67-75. doi: 10.1161/01.RES.0000134629.84732.11.
18. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, Zaccolo M. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res. 2006;98:226-234. doi: 10.1161/01.RES.0000200178.34179.93.
19. Haworth RS, Cuello F, Avkiran M. Regulation by phosphodiesterase isoforms of protein kinase A-mediated attenuation of myocardial protein kinase D activation. Basic Res Cardiol. 2011;106:51-63. doi: 10.1007/s00395-010-0116-1.
20. Nichols CB, Chang CW, Ferrero M, Wood BM, Stein ML, Ferguson AJ, Ha D, Rigor RR, Bossuyt S, Bossuyt J. β-adrenergic signaling inhibits Gq-dependent protein kinase D activation by preventing protein kinase D translocation. Circ Res. 2014;114:1398-1409. doi: 10.1161/CIRCRESAHA.114.303870.
21. Mudd JO, Kass DA. Tackling heart failure in the twenty-first century. Nature. 2008;451:919-928. doi: 10.1038/nature06798.
22. White DC, Hata JA, Shah AS, Glower DD, Lefkowitz RJ, Koch WJ. Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci U S A. 2000;97:5428-5433. doi: 10.1073/pnas.090091197.
23. Lai NC, Roth DM, Gao MH, Fine S, Head BP, Zhu J, McKirnan MD, Kwong C, Dalton N, Urasawa K, Roth DA, Hammond HK. Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation. 2000;102:2396-2401.
24. Sucharov CC, Dockstader K, Nunley K, McKinsey TA, Bristow M. β- Adrenergic receptor stimulation and activation of protein kinase A protect against α1-adrenergic-mediated phosphorylation of protein kinase D and histone deacetylase 5. J Card Fail. 2011;17:592-600. doi: 10.1016/j. cardfail.2011.03.006.
25. Simpson P. Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ Res. 1985;56:884-894.
26. Martins TJ, Mumby MC, Beavo JA. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J Biol Chem. 1982;257:1973-1979.
27. Nickl CK, Raidas SK, Zhao H, Sausbier M, Ruth P, Tegge W, Brayden JE, Dostmann WR. (D)-Amino acid analogues of DT-2 as highly selective and superior inhibitors of cGMP-dependent protein kinase Ialpha. Biochim Biophys Acta. 2010;1804:524-532. doi: 10.1016/j.bbapap.2009.12.004.
28. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222. doi: 10.1038/nm1175.
29. Hodges RR, Zoukhri D, Sergheraert C, Zieske JD, Dartt DA. Identification of vasoactive intestinal peptide receptor subtypes in the lacrimal gland and their signal-transducing components. Invest Ophthalmol Vis Sci. 1997;38:610-619.
30. Carr DW, Hausken ZE, Fraser ID, Stofko-Hahn RE, Scott JD. Association of the type II cAMP-dependent protein kinase with a human thyroid RIIanchoring protein. Cloning and characterization of the RII-binding domain. J Biol Chem. 1992;267:13376-13382.
31. McCahill A, McSorley T, Huston E, Hill EV, Lynch MJ, Gall I, Keryer G, Lygren B, Tasken K, van Heeke G, Houslay MD. In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. Cell Signal. 2005;17:1158-1173. doi: 10.1016/j. cellsig.2005.04.003.
32. Terrin A, Monterisi S, Stangherlin A, Zoccarato A, Koschinski A, Surdo NC, Mongillo M, Sawa A, Jordanides NE, Mountford JC, Zaccolo M. PKA and PDE4D3 anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosome. J Cell Biol. 2012;198:607-621. doi: 10.1083/jcb.201201059.
33. Carlson CR, Lygren B, Berge T, Hoshi N, Wong W, Taskén K, Scott JD. Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor. J Biol Chem. 2006;281:21535-21545. doi: 10.1074/jbc.M603223200.
34. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
35. Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science. 1997;275:1930-1934.
36. Sheridan CM, Heist EK, Beals CR, Crabtree GR, Gardner P. Protein kinase A negatively modulates the nuclear accumulation of NF-ATc1 by priming for subsequent phosphorylation by glycogen synthase kinase-3. J Biol Chem. 2002;277:48664-48676. doi: 10.1074/jbc. M207029200.
37. Vega RB, Rothermel BA, Weinheimer CJ, Kovacs A, Naseem RH, Bassel- Duby R, Williams RS, Olson EN. Dual roles of modulatory calcineurininteracting protein 1 in cardiac hypertrophy. Proc Natl Acad Sci U S A. 2003;100:669-674. doi: 10.1073/pnas.0237225100.
38. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004;94:110-118. doi: 10.1161/01.RES.0000109415.17511.18.
39. Asakura M, Kitakaze M, Takashima S, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002;8:35-40. doi: 10.1038/nm0102-35.
40. Zhang X, Szeto C, Gao E, et al. Cardiotoxic and cardioprotective features of chronic β-adrenergic signaling. Circ Res. 2013;112:498-509. doi: 10.1161/CIRCRESAHA.112.273896.
41. Enns LC, Bible KL, Emond MJ, Ladiges WC. Mice lacking the Cβ subunit of PKA are resistant to angiotensin II-induced cardiac hypertrophy and dysfunction. BMC Res Notes. 2010;3:307. doi: 10.1186/1756-0500-3-307.
42. Ha CH, Kim JY, Zhao J, Wang W, Jhun BS, Wong C, Jin ZG. PKA phosphorylates histone deacetylase 5 and prevents its nuclear export, leading to the inhibition of gene transcription and cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2010;107:15467-15472. doi: 10.1073/pnas.1000462107.
43. Abrenica B, AlShaaban M, Czubryt MP. The A-kinase anchor protein AKAP121 is a negative regulator of cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2009;46:674-681.
44. Nichols CB, Rossow CF, Navedo MF, Westenbroek RE, Catterall WA, Santana LF, McKnight GS. Sympathetic stimulation of adult cardiomyocytes requires association of AKAP5 with a subpopulation of L-type calcium channels. Circ Res. 2010;107:747-756. doi: 10.1161/CIRCRESAHA.109.216127.
45. Li J, Negro A, Lopez J, Bauman AL, Henson E, Dodge-Kafka K, Kapiloff MS. The mAKAPbeta scaffold regulates cardiac myocyte hypertrophy via recruitment of activated calcineurin. J Mol Cell Cardiol. 2010;48:387-394. doi: 10.1016/j.yjmcc.2009.10.023.
46. Makarewich CA, Correll RN, Gao H, Zhang H, Yang B, Berretta RM, Rizzo V, Molkentin JD, Houser SR. A caveolae-targeted L-type Ca2+ channel antagonist inhibits hypertrophic signaling without reducing cardiac contractility. Circ Res. 2012;110:669-674. doi: 10.1161/CIRCRESAHA.111.264028.
47. Rinne A, Kapur N, Molkentin JD, Pogwizd SM, Bers DM, Banach K, Blatter LA. Isoform- and tissue-specific regulation of the Ca(2+)-sensitive transcription factor NFAT in cardiac myocytes and heart failure. Am J Physiol Heart Circ Physiol. 2010;298:H2001-H2009. doi: 10.1152/ajpheart.01072.2009.
48. Mehel H, Emons J, Vettel C, et al. Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes. J Am Coll Cardiol. 2013;62:1596-1606. doi: 10.1016/j. jacc.2013.05.057.
49. Hua R, Adamczyk A, Robbins C, Ray G, Rose RA. Distinct patterns of constitutive phosphodiesterase activity in mouse sinoatrial node and atrial myocardium. PLoS One. 2012;7:e47652. doi: 10.1371/journal. pone.0047652.
50. Aye TT, Soni S, van Veen TA, van der Heyden MA, Cappadona S, Varro A, de Weger RA, de Jonge N, Vos MA, Heck AJ, Scholten A. Reorganized PKA-AKAP associations in the failing human heart. J Mol Cell Cardiol. 2012;52:511-518. doi: 10.1016/j.yjmcc.2011.06.003.
51. Perrino C, Naga Prasad SV, Mao L, Noma T, Yan Z, Kim HS, Smithies O, Rockman HA. Intermittent pressure overload triggers hypertrophyindependent cardiac dysfunction and vascular rarefaction. J Clin Invest. 2006;116:1547-1560. doi: 10.1172/JCI25397.
52. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580-1589. doi: 10.1161/01. CIR.0000120390.68287.BB.
53. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, Rockman HA. Genetic alterations that inhibit in vivo pressureoverload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 2002;105:85-92.
54. Koitabashi N, Kass DA. Reverse remodeling in heart failure-mechanisms and therapeutic opportunities. Nat Rev Cardiol. 2012;9:147-157. doi: 10.1038/nrcardio.2011.172.
55. Bristow MR. Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011;109:1176-1194. doi: 10.1161/CIRCRESAHA.111.245092.
56. Metra M, Eichhorn E, Abraham WT, et al; ESSENTIAL Investigators. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009;30:3015-3026. doi: 10.1093/eurheartj/ehp338.
57. Gesztelyi R, Zsuga J, Hajdú P, Szabó JZ, Cseppento A, Szentmiklósi AJ. Positive inotropic effect of the inhibition of cyclic GMPstimulated 3', 5'-cyclic nucleotide phosphodiesterase (PDE2) on guinea pig left atria in eu- and hyperthyroidism. Gen Physiol Biophys. 2003;22:501-513.